Abstract:More than fifteen years after their discovery, IDH mutations remain as intriguing as ever. Three mutational hotspots are described in different cancers, including glioma, chondrosarcoma, or hematological diseases, resulting in single amino acid substitutions in two of the IDH genes (IDH1R132, IDH2R172 and IDH2R140). Wild-type IDH1/2 catalyze the conversion of isocitrate into α-ketoglutarate (α-KG), and their mutations confer neomorphic activity to this metabolic enzyme, reducing α-KG to 2-hydroxyglutarate (2-HG). 2-HG is a potent inhibitor of several dioxygenases that normally use α-KG as a cofactor. Among them is the ten-eleven translocation (TET) family, which catalyzes the hydroxylation of methylated cytosine bases in the DNA. Mutations in epigenetic regulators, such as IDH, are commonly found in hematological malignancies including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and peripheral T cell lymphoma (PTCL), and especially angioimmunoblastic T cell lymphoma (AITL). Despite many advances, these hematologic diseases still have significant unmet medical needs, and require novel approaches to patient selection and therapy. IDH inhibitors are currently under investigation in MDS, AML and PTCL and have shown promise in early clinical trials for AML and MDS. However, not all IDH-mutant patients respond, and resistance frequently develops. Changes to epigenetic regulation and diversity driven by IDH1/2 mutations likely contribute to these effects, but our incomplete understanding of the underlying biology limits therapeutic intervention. Establishing the relationship between tumor genetics and human diseases in the context of IDH mutations is challenging. The distribution of the three hotspot mutations among the different pathologies is complex and not yet fully understood. An intriguing fact is that IDH2R140 mutation is exclusively found in myeloid malignancies. Furthermore, clinical data indicate that the co-mutational pattern of IDH1/2 mutations is associated differently in hematological disorders. For instance, IDH1/2 and TET2 mutations are essentially mutually exclusive in myeloid context but frequently co-occur in AITL, suggesting that their effects in specific cell types and disease contexts may differ. Understanding how IDH1/2 and TET2 mutations drive malignancy and why they cooperate differently in myeloid and lymphoid diseases can help distinguish common from specific mechanisms in myeloid and lymphoid compartments, revealing specific tumor cell vulnerabilities, which could be targeted to improve patient outcomes. The laboratory of Professor Mak has generated three strains of Idh knock-in mice, each bearing one of the three hotspot mutations and has assembled a multidisciplinary team in epigenetics and clinical investigation to explore their role and set the stage for further mechanistic insight into mutant IDH, both in myeloid or lymphoid contexts. 2-HG levels differ between the myeloid and lymphoid lineages of each strain and may explain the variations in the mutational spectrum associated with different cellular contexts. Even within the myeloid lineage, analyses of these three Idh-mutant mice suggest that these alleles produce phenotypes of varying severity, correlating with 2-HG levels, with Idh2R172 exhibiting the most severe phenotype. We showed that altered DNA and histone methylation; partially block hematopoietic cell differentiation at the hematopoietic stem cell/progenitor stage; resulting in a hematopoietic phenotype reminiscent of human MDS. Given the mutual exclusivity of IDH1/2 and TET2 mutations in myeloid neoplasms, it has been hypothesized that they converge on a common oncogenic pathway. However, in a first study, we demonstrated that mutant Idh1 impairs DNA repair via a mechanism independent of Tet2 at the stem cell stage. Then, in a second study, we showed that these alterations have distinct, and even opposite, effects on hematopoietic stem cells and progenitors. Epigenetic and single-cell transcriptomic analyses revealed that Idh2R172 and Tet2 mutations had diverging consequences. Our data argue against a simple equivalence of Idh1/2 and Tet2 mutations, and may help to explain some of the clinical differences between TET2- and IDH-mutant in a myeloid context. In PTCL, the neoplastic cells represent a minor part of the tumor, a truth that is even more pronounced in AITL, where the microenvironment frequently accounts for 90% of the tumoral mass. Using molecular and histological approaches, it has been shown that driving mutations, such as TET2, occur in hematopoietic stem cells, and are found in both malignant and non-malignant cells. On the other hand, others alterations, such as IDH2, occur in mature T cells, specifically in T follicular helper (TFH) cells, and are restrictive to malignant cells. Our team, in collaboration with a group of researchers led by Drs. Philippe Gaulard and François Lemonnier, -Abstract Truncated-

Can Ruxolitinib Crash TET2 - and IDH2 -Driven Clonal Hematopoiesis?

Cell of Origin Epigenetic Priming Determines Susceptibility to Tet2 Mutation

Ruxolitinib/nilotinib Cotreatment Inhibits Leukemia-Propagating Cells in Philadelphia Chromosome-Positive ALL.

CRISPR Dependency Screens in Primary Hematopoietic Stem Cells Identify KDM3B as a Genotype Specific Vulnerability in IDH2- and TET2-Mutant Cells

Abstract SY16-01: What IDH mouse models have taught us about hematological diseases, from leukemia to T cell lymphoma

Abstract 2934: TET2 deficiency accelerates leukemogenesis in the NHD13 mouse model of MDS

Abstract P073: Targeting JAK1 signaling for molecular prevention in clonal hematopoiesis

Clonal hematopoiesis related TET2 loss-of-function impedes IL1β-mediated epigenetic reprogramming in hematopoietic stem and progenitor cells

Ruxolitinib Plus Decitabine Effectively Treats Myelodysplastic Syndrome/Myeloproliferative Neoplasm, Unclassifiable, by Decreasing the Variant Allele Frequency of KRAS

Id1 Promotes Clonal Hematopoiesis in Mice with Tet2 Loss of Function

Hematopoietic Tet2 inactivation enhances the response to checkpoint blockade immunotherapy

Ruxolitinib Monotherapy for a Child With HAVCR2 Gene Mutation Associated Subcutaneous Panniculitis-like T-cell Lymphoma: A Case Report

TET2 mutation as Prototypic Clonal Hematopoiesis Lesion

Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations

Human Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK1/2 Blockade

Type II mode of JAK2 inhibition and destabilization are potential therapeutic approaches against the ruxolitinib resistance driven myeloproliferative neoplasms

Abstract 280: Aberrant β-catenin signaling from the bone marrow niche leads to transformation of IDH1/2 -mutant hematopoietic stem cells and compromises response to IDH1/2 inhibitors

T cells take aim in AML: targeting IDH2

Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation

Loss Of Epigenetic Regulator Tet2 And Oncogenic Kit Regulate Myeloid Cell Transformation Via Pi3k Pathway

Targeting SRSF2 mutations in leukemia with RKI-1447: A strategy to impair cellular division and nuclear structure